IXALTIS

Executive Summary

IXALTIS is a French biopharmaceutical company dedicated to developing innovative therapies for genitourinary tract disorders. Founded in 2012 and headquartered in Lyon, the company's portfolio is built on an exclusive worldwide license from Sanofi for three clinical-stage compounds targeting conditions such as overactive bladder and interstitial cystitis. By leveraging these differentiated assets, IXALTIS aims to address significant unmet medical needs in urology. The company operates as a private entity and has not disclosed specific financial details or valuation. With a focused pipeline and a strategy centered on repurposing and advancing late-stage candidates, IXALTIS is positioned to generate clinical data in the near term. However, limited public information on trial progress and competitive dynamics introduces execution risk. Overall, IXALTIS represents a targeted play in urology with defined catalysts from its Sanofi-derived programs.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b top-line data for lead compound in overactive bladder60% success
• Q1 2027Initiation of Phase 3 trial for interstitial cystitis candidate70% success
• Q4 2026Potential licensing or partnership deal for non-core asset40% success